Related Experiment Video

Updated: Feb 3, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

904

ErbB4/KITENIN-Mediated Signaling is Activated in Cetuximab-Resistant Colorectal Cancer Cells

So-Yeon Park1, Yi Yang1, Rui Zhou1

  • 1College of Pharmacy, Sunchon National University, Sunchon, Jeonnam, 57922, Korea.

Journal of Nanoscience and Nanotechnology
|October 27, 2018
PubMed

Insights

ErbB4/KITENIN signaling activation drives resistance to anti-EGFR therapy in colorectal cancer. Targeting ErbB4/KITENIN may overcome this resistance, improving treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in colorectal cancer (CRC) progression.
  • EGFR-independent pathways, like ErbB4/KITENIN, also contribute to CRC invasiveness and tumorigenesis.
  • The role of ErbB4/KITENIN signaling in resistance to anti-EGFR therapy is not well understood.

Purpose of the Study:

  • To investigate the involvement of ErbB4/KITENIN signaling in cetuximab resistance in colorectal cancer cells.
  • To determine if targeting ErbB4/KITENIN signaling can overcome cetuximab resistance.

Main Methods:

  • Establishment of cetuximab-resistant DLD1 and HT29 colorectal cancer cell lines.
  • Analysis of ErbB4/KITENIN signaling pathway components (c-Jun, KITENIN, phosphorylated EGFR, phosphorylated ErbB4).
  • Assessment of cetuximab sensitivity following KITENIN and/or ErbB4 gene silencing.

Main Results:

  • Cetuximab-resistant cells showed upregulated c-Jun and increased phosphorylation of EGFR and ErbB4.
  • KITENIN protein levels remained constant in resistant cells.
  • Silencing KITENIN and/or ErbB4 restored sensitivity to cetuximab in resistant cells.

Conclusions:

  • ErbB4/KITENIN signaling is activated in cetuximab-resistant colorectal cancer cells.
  • This activated signaling pathway contributes to the development of resistance to anti-EGFR therapy.
  • Targeting ErbB4/KITENIN represents a potential therapeutic strategy to overcome anti-EGFR resistance in CRC.

More Related Videos

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
What is Cell Signaling?02:03

What is Cell Signaling?

Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
130.4K
Cell-surface Signaling01:21

Cell-surface Signaling

Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
54.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
110.9K
Paracrine Signaling01:21

Paracrine Signaling

Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...
59.6K